HELX : Franklin Genomic Advancements ETF

HELX is a Other Market with HIGH fees.

HELX

Franklin Genomic Advancements ETF

FI Score

35 /100

Expense Ratio Rating

0 /10

Expense Rating

5 /10

Market Score

6 /10

Category Score

0 /10

Market Size

6 /10

35% FI Score
  • helx
  • ETF
  • Other

Franklin Genomic Advancements ETF

Expenses: 0.50% (Better than 0% of similar funds)

This is a bad choice for a Other fund. See why ยป

Fund Summary

The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.

Largest Holdings

Amount Holding
4.44% Illumina, Inc
4.40% Repligen Corporation
4.25%
4.06% Lonza Group Ltd
3.74% Veeva Systems Inc
3.72% Vertex Pharmaceuticals Incorporated
3.30% CRISPR Therapeutics AG
3.26% Catalent, Inc
3.16% uniQure N.V
2.85% Agilent Technologies, Inc

Minafi - The intersection of FI, minimalism & mindfulness.

Don't miss out on new posts, courses, interactive articles and more!

Join & Get Your First Course Free

© 2021   Adam Fortuna

Site Map
Triangle Graduation Cap Angle Down Book regular Phone laptop regular fire regular fire regular search regular Acorn duotone Seedling duotone thumbs down duo